2486 Dunwin Drive
133 articles with Acerus Pharma
Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor™ Application
Acerus Pharmaceuticals Corporation is today advising that it has received a Notice of Deficiency-Withdrawal Letter (“Notice”) for its GynoflorTM New Drug Submission.
Acerus Pharmaceuticals Corporation is today advising that it has reported an anticipated shortage of certain doses of ESTRACE® on the Drug Shortages Canada website in relation to supply issues arising from the Company’s contract manufacturer.
Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
The THC trial, previously announced on October 24, 2018, involved 12 overnight-fasting, healthy subjects with prior cannabis experience.
Acerus Pharmaceuticals Corporation is today providing an update on a number of significant operational and research achievements related to NATESTO®, one of the Company’s core strategic assets.
Increased product revenue by 16% to $1.6 million versus $1.4 million in the same three-month period in the prior year.
Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
--Amended Agreement Now Covers the Current EU Member States (including the UK) plus Eight Other Countries--
– Robert Motz joins Acerus as Chief Financial Officer –
Acerus Pharma (the “Company” or “Acerus”) (TSX:ASP) today announced that it has entered into a senior secured term loan credit facility with SWK Funding LLC (“SWK”) for up to US$11 million (the “New Facility”).
Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study
Early Data Suggests Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonadal Men Taking Natesto®
Acerus Pharmaceuticals Corporation reported its financial results for the three months and six months ended June 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.
This approval marks an important milestone in establishing NATESTO® globally as this is the first regulatory approval outside of North America
Acerus Pharmaceuticals Corporation announced that Mr. Luc Mainville has stepped down as a director of the company.
Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest
Acerus Pharmaceuticals Corporation today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.
Product revenues increased 60% to $1.6 million versus $1.0 million in the same prior year period
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the signing of an agreement granting Producto Científicos, S.A. de C.V (“Carnot Laboratorios”) the exclusive right to market NATESTO® in 19 Central and Latin American countries
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that the Company and certain of its present and former directors and officers have reached a settlement with Eugene Melnyk
Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.
Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2017.
Acerus Pharma’s NATESTO to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2017
Acerus Pharma announced that it has received notice from Quebec’s National Institute for Excellence in Health and Social Services (INESSS) of a positive recommendation to the Health Minister for the inclusion of NATESTO® on the list of medications of the Régie de l’assurance maladie du Québec.
Acerus today announced that it has received a Notice of Deficiency (“NOD”) for its Gynoflor New Drug Submission.